A phase II efficacy and safety study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer.

Ju‐Dong Li, Lee Li, Ziyi Wang et al.|Journal of Clinical Oncology|2025

Cited by 4